BillWalshCommunity.com_AAA Cell Phones And Driving Research UpdateBillWalsh Honda
Cell phone use while driving poses significant risks, according to two surveys conducted by AAA Foundation. The surveys found over half of drivers admit to talking on a cell phone while driving at least occasionally, with 16-17% doing so regularly. Younger drivers aged 25-34 reported the highest rates of cell phone use while driving. Additionally, 14-17% of drivers admit to reading or sending text messages while driving occasionally, with 3% doing so regularly. However, many drivers do not perceive the risks of cell phone use while driving, with 46% admitting to the behavior despite saying it is a serious problem, and many believing hands-free use is safer despite studies showing otherwise.
BillWalshCommunity.com_AAA Cell Phones And Driving Research UpdateBillWalsh Honda
Cell phone use while driving poses significant risks, according to two surveys conducted by AAA Foundation. The surveys found over half of drivers admit to talking on a cell phone while driving at least occasionally, with 16-17% doing so regularly. Younger drivers aged 25-34 reported the highest rates of cell phone use while driving. Additionally, 14-17% of drivers admit to reading or sending text messages while driving occasionally, with 3% doing so regularly. However, many drivers do not perceive the risks of cell phone use while driving, with 46% admitting to the behavior despite saying it is a serious problem, and many believing hands-free use is safer despite studies showing otherwise.
The document outlines the goals and strategy of the STAR initiative to accelerate research for Charcot-Marie-Tooth disease (CMT). The initiative aims to introduce effective CMT therapies within 5-10 years by focusing research on treatments, fostering collaboration between scientists, and exclusively funding strategic research plans. A key part of the strategy involves screening FDA-approved drugs to identify potential treatments for CMT1A, the most common type of CMT, using cell lines and animal models.
The document outlines the goals and strategy of the CMTA's STAR initiative to accelerate research for Charcot-Marie-Tooth disease. The initiative aims to introduce effective CMT therapies within 5-10 years by focusing collaborative research efforts on treatments and cures. A key part of the strategy involves screening FDA-approved drugs using a cell line from the most common CMT1A subtype to identify candidate compounds for further animal and human testing.